FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Kinetics topics
Medical Device
Polypeptide
Nucleic Acid
Nucleic Acids
Specificity
Surfactant
Enhancement
Scattering
Electrolyte
Conductive Elements
Amplification
Red Blood Cell
Red Blood Cells
Antibodies
Luciferase

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Kinetics patents



      
           
This page is updated frequently with new Kinetics-related patent applications. Subscribe to the Kinetics RSS feed to automatically get the update: related Kinetics RSS feeds. RSS updates for this page: Kinetics RSS RSS


Council Of Scientific & Industrial Research

Device for thermokinetic property measurement

Date/App# patent app List of recent Kinetics-related patents
05/21/15
20150140636
 Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression patent thumbnailnew patent Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression
The invention provides a mutant hydrolase protein with enhanced kinetics and functional expression, as well as polynucleotides encoding the mutant proteins and methods of using the polynucleotides and mutant proteins.. .
Promega Corporation
05/21/15
20150139269
 Device for thermokinetic property measurement patent thumbnailnew patent Device for thermokinetic property measurement
A device which can be used as a flow reactor for synthesis and for discerning the reaction kinetics as well as a flow calorimeter is a need in the art. To fulfill this need, the invention discloses a simple calorimeter that functions as a device to measure reaction kinetics, preferably heat of reaction in a continuous manner, in adiabatic as well as in isothermal conditions.
Council Of Scientific & Industrial Research
05/14/15
20150134296
 Method for determining functional volumes for determining biokinetics patent thumbnailMethod for determining functional volumes for determining biokinetics
A method for determining functional volumes for the search for kinetics representing the trend of concentration of a radioactive tracer in an area of biological tissue, being applied to spatial components comprises the following steps applied iteratively according to a markov chain monte-carlo scheme: generation of a set k0λ made up of a set of candidate kinetics associated with values of probability of appearance, depending on the concentration λ of radioactive tracer; a labeling step during which, for each spatial component of index k, the probabilities of selection of the kinetics of the set k0λ are weighted by introducing a function λk representative of the concentration of radioactive tracer in this component to obtain a set of indicative values, an indicative value dk designating the kinetic with which the spatial component k is associated; construction of functional volumes, a functional volume vfj made up of the set of spatial components which share the same indicative value dk.. .
05/14/15
20150133639
 Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins patent thumbnailUse of metal ions for modulation of protein glycosylation profiles of recombinant proteins
Protein glycosylation greatly influences the structure, function, and pharmacokinetics of recombinant proteins. Here, growth media supplemented with metal ions is shown to modulate the protein glycosylation profile of recombinant proteins expressed in a variety of eukaryotic cell lines.
05/14/15
20150133369
 Pharmacokinetic modulation with alisporivir patent thumbnailPharmacokinetic modulation with alisporivir
A method of using alisporivir to therapeutically alter the pharmacokinetics of a medication whereby alisporivir has an effect that achieves and preserves similar safety and efficacy of said drugs with lower doses, less frequent administration, or both.. .
05/14/15
20150132781
 Multiplexed chromatography-immunoassay  the characterization of circulating immune complexes patent thumbnailMultiplexed chromatography-immunoassay the characterization of circulating immune complexes
Thus, herein is reported a method for analyzing/characterizing circulating immune complexes (cics) formed in vivo comprising a size-exclusion chromatography of a sample obtained from a mammal to which the drug had been administered at least once for determining the weight/size of the immune complexes, optionally a second non-sec chromatography, and at least one immunoassay, whereby the immune complex is characterized by the correlation of the immune complex size and the immunoassay result/read-out. Also reported herein is the use of a method as reported herein for determining a correlation to altered pharmacokinetics, for determining loss or reduction of efficacy, for determining neutralization of natural counterparts of the drug, for determining immune and hypersensitivity reactions, including serum sickness/type iii hypersensitivity reaction/immune complex-mediated disease..
05/07/15
20150123096
 Multilayer light-emitting electrochemical cell device structures patent thumbnailMultilayer light-emitting electrochemical cell device structures
Novel structures and compositions for multilayer light-emitting electrochemical cell devices are described, particularly those that are adapted to work with stable and printable electrode metals, that optimize recombination efficiency, lifetime and turn-on kinetics. In particular, embodiments of the present invention provide improved performance and extended lifetime for doped electronic devices, where ionic doping levels, ionic support materials content, and electronic transport content are advantageously structured within the device.
Sumitomo Chemical Company Limited
04/30/15
20150118679
 Methods and  single molecule sequencing using energy transfer detection patent thumbnailMethods and single molecule sequencing using energy transfer detection
Provided herein are systems and methods for nucleotide incorporation reactions. The systems comprise polymerases having altered nucleotide incorporation kinetics and are linked to an energy transfer donor moiety, and nucleotide molecules linked with at least one energy transfer acceptor moiety.
Life Technologies Corporation
04/30/15
20150118285
 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces patent thumbnailPharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers.
Biodelivery Sciences International, Inc.
04/09/15
20150099001
 Nanocell drug delivery system patent thumbnailNanocell drug delivery system
Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
Massachusetts Institute Of Technology
04/02/15
20150094369

Water temperature as a means of controlling kinetics of onsite generated peracids


Methods and systems for temperature-controlled, on-site generation of peracids, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions are disclosed. In particular, methods for using an adjustable biocide formulator or generator system overcome the limitations of temperature on the kinetics of the peracid generation and/or peracid decomposition inside an adjustable biocide formulator or generator system.
Ecolab Usa Inc.
03/26/15
20150087676

Diamide inhibitors of cytochrome p450


Methods of inhibiting cytochrome p450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome p450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome p450 enzymes..
Sequoia Pharmaceuticals, Inc
03/19/15
20150080844

Therapy for kidney disease and/or heart failure by intradermal infusion


Intradermal delivery devices, systems and methods thereof for the administration of a natriuretic or chimeric peptide are described. The described delivery devices, systems and methods provide for the treatment of pathological conditions such as kidney disease alone, heart failure alone, concomitant kidney disease and heart failure, or cardiorenal syndrome by delivery of a natriuretic or chimeric peptide through a microneedle array using a delivery pump.
Medtronic, Inc.
03/19/15
20150080580

Thiourea derivatives as a-chymotrypsin inhibitors


α-chymotrypsin inhibitors of thiourea class are reported that could be potent inhibitors of proteases, elastases, proteasomes, ns3 and ns4 serine protease of hepatitis c virus, dengue virus, etc. Compounds 1-22, which are belong to thiourea class, showed good inhibition.
03/19/15
20150079619

Aqueous methacetin solutions labelled with 13c having propylene glycol as a solubilizer


An analysis method determines a functional parameter of an organ by measuring 13co2 content in exhaled air of an individual to which a substrate has been administered. The reaction of the substrate in the body of the individual enriches the exhaled air with 13co2.
CharitÉ UniversitÄtsmedizin Berlin
03/19/15
20150076034

Coking process and system for enhanced catalytic reactions to improve process operation and economics


Heavy gas oil components, coking process recycle, and heavier hydrocarbons in the delayed coking process are cracked in the coking vessel by injecting a catalytic additive into the vapors above the gas/liquid-solid interface in the coke drum during the coking cycle. The additive may comprise cracking catalyst(s) and quenching agent(s), alone or in combination with seeding agent(s), excess reactant(s), carrier fluid(s), or any combination thereof to modify reaction kinetics to preferentially crack these components.
03/19/15
20150076032

System and introducing an additive into a coking process to improve quality and yields of coker products


Heavy gas oil components, coking process recycle, and heavier hydrocarbons in the delayed coking process are cracked in the coking vessel by injecting a catalytic additive into the vapors above the gas/liquid-solid interface in the coke drum during the coking cycle. The additive comprises cracking catalyst(s) and quenching agent(s), alone or in combination with seeding agent(s), excess reactant(s), carrier fluid(s), or any combination thereof to modify reaction kinetics to preferentially crack these components.
02/26/15
20150057986

Method for predicting occurrence of microquartz in a basin


A method, including: obtaining a grain size for amorphous silica associated with a basin and a grain size for quartz associated with the basin; obtaining kinetics of silica dissolution corresponding to the basin and quartz precipitation corresponding to the basin; determining, with a processor, a concentration of amorphous silica in water based on the grain size for amorphous silica, the grain size for quartz, and the kinetics of silica dissolution and quartz precipitation; comparing, with the processor, the concentration of amorphous silica in water to an amorphous silica saturation condition; and determining, with the processor, a presence of microquartz based on a result of the comparing.. .
02/19/15
20150052623

Genetically modified rat models for pharmacokinetics


The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the slc7a11 (nc_005101.2) gene, the abcb1 (nc_005103.2) gene, etc.
Transposagen Biopharmaceuticals, Inc.
02/19/15
20150051153

Environmentally sensitive compositions


An environmentally sensitive membrane binding polypeptide, ph (low)-sensitive membrane peptide (phlip) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.. .
02/12/15
20150045505

New formulation methodology for distortional thermosets


And a diamine curing agent. The resultant distortional thermoset compositions possess superior out-life requirements and advantageous reaction kinetics for preparing prepreg compositions and materials..
02/12/15
20150044208

Modified albumin-binding domains and uses thereof to improve pharmacokinetics


The present invention relates to compositions and methods comprising a modified albumin-binding domain to improve the pharmacokinetic properties of therapeutic molecules. The modified peptides show reduced immunogenicity and/or proved solubility.
Technophage, InvestigaÇÄo E Desenvolvimento Em Biotecnologia, Sa
01/29/15
20150031926

Methods for liquid-phase reactions


Methods and assemblies for improving the reaction kinetics of, conserving reactants utilized in, and/or producing a more pure reaction product of, liquid-phase reactions that involve volatile reactants and products are provided. The methods and assemblies herein provide for a feed of reaction liquid to two or more absorption zones, wherein the temperature and/or feed rate of the liquid is independently adjusted prior to introduction into at least one of the two or more absorption zones.
Dow Global Technologies Llc
01/29/15
20150031734

Pharmaceutical composition containing mirabegron


Provided is a mirabegron-containing pharmaceutical composition in which the leakage of mirabegron can be inhibited when the pharmaceutical composition is dispersed in a liquid, and in which the change in pharmacokinetics caused by the presence or absence of food intake is decreased. The pharmaceutical composition comprises an acid addition salt of alkyl sulfuric acid and mirabegron, and a base for modified release..
Astellas Pharma Inc.
01/22/15
20150025419

Integrated triad system for providing advanced assessment methods, corrective and performance exercise training, and integrating specialized manual therapies


The ortho-kinetics system is a biomechanically based system that, through systematic assessment, analysis, and evaluations, one can identify a person's anomalies such as postural deviations, joint limitations, neuromuscular imbalances, and movement compensations. This system makes use of a database which stores expert-derived information to guide the practitioner in the administration and performance of advanced assessment methods and programming process, corrective and performance exercise training, along with integration of specialized manual therapies..
01/22/15
20150022815

Quantum chemical analysis


A new trend in chemical analysis is introduced including design of new instruments used for counting of molecules and enantiomers in a given solution. The method is mainly based on quantum optics and quantum chemistry which are the reasons for the expression “quantum chemical analysis”.
01/15/15
20150017720

Therapeutic uses of curcumin analogs for treatment of prostate cancer


This invention relates generally to methods of treating aggressive cancers, such as hormone-refractory metastatic prostate cancer, by exposing the aggressive cancer cells to curcumin analogs having the claimed structural scaffolds and side groups. The anticancer effects of curcumin are associated with its influence on numerous growth factors within the cells.
California State University Fresno
01/15/15
20150014253

Removal of heavy metals from aqueous solutions using metal-doped titanium dioxide nanoparticles


The removal of heavy metals from aqueous solutions using metal-doped titanium dioxide nanoparticles is a method that comprises contacting the aqueous solution with metal-doped titanium dioxide nanoparticles. The three transition metals tungsten, vanadium and iron were selected for doping of titanium dioxide.
King Fahd University Of Petroleum And Minerals
01/08/15
20150011672

Silicone hydrogels having a structure formed via controlled reaction kinetics


The present invention relates to a process comprising the steps of reacting a reactive mixture comprising at least one silicone-containing component, at least one hydrophilic component, and at least one diluent to form an ophthalmic device having an advancing contact angle of less than about 80°; and contacting the ophthalmic device with an aqueous extraction solution at an elevated extraction temperature, wherein said at least one diluent has a boiling point at least about 10° higher than said extraction temperature.. .
Johnson & Johnson Vision Care, Inc.
01/08/15
20150010629

Controlled release and taste masking oral pharmaceutical composition


Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. A structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices.
Cosmo Technologies Limited
01/01/15
20150005595

Implantable devices and methods for evaluation of active agents


Devices for the local delivery of microdose amounts of one or more active agents, alone or in combination, in one or more dosages, to selected tissue of a patient are described. The devices generally include multiple microwells arranged on or within a support structure and contain one or more active agents, alone or in combination, in one or more dosages and/or release pharmacokinetics.
Kibur Medical, Inc.
01/01/15
20150004627

Method and detection of a biomarker by alternating current electrokinetics


Systems, methods and a lab-on-a-chip product are described for the detection of pathogens, infectious diseases and physiological conditions by quantifying change over time of one of capacitance or impedance when a biological sample is loaded onto the chip. The lab-on-a-chip utilizes ac electrokinetic phenomena such that molecules move or are carried in an electric field generated by the application of a signal of predetermined voltage and frequency to an electrode array.
University Of Tennessee Research Foundation
01/01/15
20150004231

Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2


The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (vmat2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.. .
Auspex Pharmaceuticals, Inc.
12/18/14
20140371436

Novel polyene compound, preparing the same, and antifungal drug comprising novel polyene compound asactive ingredient


The present invention relates to a novel polyene compound similar to nystatin, a method for preparing the same, and an antifungal drug comprising the novel polyene compound as an active ingredient. Compared to nystatin comprising one sugar, nnp, which is the polyene compound similar to nystatin, displays 300 times higher solubility and ten times lower cytotoxicity while maintaining antifungal activity, and thus can be useful in developing a novel polyene antifungal agent having improved solubility and less toxicity in terms of pharmacokinetics..
Inha-industry Partnership Institute
12/18/14
20140371181

Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens


Prodrugs of c-17-heterocyclic-steroidal drugs providing improved oral bioavailability and phamacokinetics are described. The drugs are inhibitors of human cyp 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (ar), and are useful for the treatment of urogenital and/or androgen-related cancers, diseases and/or conditions, such as human prostate cancer, breast cancer, and prostate hyperplasia.
Tokai Pharmaceuticals, Inc.
12/18/14
20140370108

Pharmacokinetics of s-adenosylmethionine formulations


Compositions and methods to improve the pharmacokinetic profile of s-adenosylmethionine (same) are provided, as are methods of treating various disorders using same formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous same.
Methylation Sciences International Srl
12/18/14
20140370001

Ige antibodies for the inhibition of tumor metastasis


The present invention provides novel ige antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor..
The Board Of Trustees Of The Leland Stanford Junior University
12/11/14
20140365640

Method, apparatus, and computer program product for performance analytics determining location based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining location based on participant dynamics/kinetics models. In one embodiment, a method is provided for monitoring a participant that at least includes correlating at least one tag to the participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
12/11/14
20140365194

Method, apparatus, and computer program product for dynamics/kinetics model selection


Provided herein are systems, methods and computer readable media for assessing the health, fitness, operation, or performance of an individual. An example method comprises selecting an individual dynamics/kinetics model from a database and comparing it to tag location data.
12/11/14
20140364977

Method, apparatus, and computer program product for evaluating performance based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics for evaluating performance using real time data on movement and proximity of tagged objects. In one embodiment, a method is provided for evaluating a player that includes correlating at least one tag to the player; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
12/11/14
20140364976

Performance analytics based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing performance analytics using dynamics/kinetics models based on role data or weather data and real time data on movement and proximity of tagged objects. In one embodiment, a method is provided for monitoring a participant that at least includes correlating at least one tag to the participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
12/11/14
20140364975

Method, apparatus, and computer program product for combined tag and sensor based performance modeling using real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing performance modeling by combining tags and sensors providing real time data on movement and proximity of tagged objects. In one embodiment, a method is provided for monitoring a participant that at least includes correlating at least one tag to the participant; receiving blink data transmitted by the at least one tag; determining tag location data based on the blink data; correlating a sensor to the participant; and receiving sensor derived data.
12/11/14
20140364974

Method, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining play models and outputting events. In one embodiment, a method is provided for determining play data that at least includes correlating at least one tag to a participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
12/11/14
20140364973

Method, apparatus, and computer program product for monitoring health, fitness, operation, or performance of individuals


Provided herein are systems, methods and computer readable media for monitoring the health and fitness of an individual. An example method comprises correlating a tag and a sensor to the individual, receiving tag derived data indicative of a location for the individual, and receiving sensor derived data indicative of at least one of a health, a fitness, an operation level, or a performance level for the individual.
12/11/14
20140364577

Enhancing the physical properties of semi-crystalline polymers via solid-state shear pulverization


Solid-state shear pulverization of semi-crystalline polymers and copolymers thereof and related methods for enhanced crystallization kinetics and physical/mechanical properties.. .
12/11/14
20140363497

Nanocell drug delivery system


Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
12/11/14
20140363428

Therapeutic antigen-binding molecule with a fcrn-binding domain that promotes antigen clearance


The present invention provides: a modified fcrn-binding domain having an enhanced affinity for the fc receptor neonatal (fcrn) at neutral ph; an antigen-binding molecule comprising said fcrn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased fcrn-binding activity at neutral or acidic ph without an increased binding activity at neutral ph for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified fcrn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified fcrn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug antibody; and methods for producing said antigen-binding molecules.. .
12/11/14
20140361890

Method, apparatus, and computer program product for alert generation using health, fitness, operation, or performance of individuals


Provided herein are systems, methods and computer readable media for monitoring the health and fitness of an individual. An example method comprises correlating a tag to the individual and receiving tag derived data indicative of a location for the individual, or correlating a sensor to the individual and receiving sensor derived data indicative of at least one of a health, a fitness, an operation level, or a performance level for the individual.
12/04/14
20140357554

Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin


Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“edta”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients.
12/04/14
20140357527

Method and measuring phosphorylation kinetics on large arrays


The disclosure provides for methods and apparatuses relating to technology for monitoring chemical and/or biological reactions. Some methods provided herein relate to utilization of nappa technology to create large protein arrays suitable for use in combination with various isfet arrays to enable massive parallel assays of kinase activity and inhibition.
11/27/14
20140349959

Polysaccharide gel formulation having increased longevity


Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.
11/27/14
20140348963

Pharmaceutical platform technology for the development of natural products


The present invention provides a set of in vitro and in silico methodologies for predicting in vivo pharmacokinetics and pharmacodynamics of multiple components; the methodologies comprise mathematical models for solving multiple unknowns which are linearly independent and/or interacting with each other. The present invention can be applied to develop phytomedicines which contain multiple active ingredients without prior identification, isolation and purification of these components..
11/20/14
20140343078

Compositions and methods for inhibiting cytochrome p450 2d6


Methods of inhibiting cytochrome p450 2d6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome p450 2d6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome p450 2d6 enzymes..
11/20/14
20140341994

Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2


The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (vmat2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.. .
11/13/14
20140336681

Methods and devices for connecting nerves


A nerve repair conduit configured to be secured on first and second portions of a selected nerve. The nerve repair conduit includes a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen.
11/13/14
20140336386

Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2


The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (vmat2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.. .
11/13/14
20140335157

Cationic lipid having improved intracellular kinetics


And use thereof.. .
11/06/14
20140329810

Aerosol fluoroquinolone formulations for improved pharmacokinetics


The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract..
10/30/14
20140323289

Zeolitic adsorbents for use in adsorptive separation processes and methods for manufacturing the same


A method for producing a zeolitic adsorbent includes providing a zeolite material, providing a zeolite material, providing a first clay binder material and a second clay binder material, the first clay binder material having a greater median particle size than the second clay binder material, determining a desired adsorption kinetics rate for the zeolitic adsorbent, wherein the desired adsorption kinetics rate is based at least in part on a separations process in which the zeolitic adsorbent is desired to be employed, and selecting either the first clay binder material or the second clay binder material based at least in part on the determined desired adsorption kinetics rate. The method further includes blending the zeolite material and the selected first or second clay binder material to form a zeolite/binder blended system, forming a plurality of shaped zeolitic adsorbent pieces from the exchanged zeolite/binder blended system, binder-converting the clay binder material into a zeolite material, and ion-exchanging the binder-converted shaped pieces with an exchange cation to form an ion-exchanged zeolite/binder blended system..
10/30/14
20140322737

Fast reaction kinetics of enzymes having low activity in dry chemistry layers


The present invention concerns a method for determining an analyte as well as a diagnostic element suitable therefore. In one particular form, a method for determining an analyte includes contacting a sample containing the analyte with a diagnostic element comprising a dry reagent layer.
10/30/14
20140320958

Mode-switchable illumination system for a microscope


Illumination system for a microscope system capable of being mode-switchable between a first and a second illumination mode, comprising one source of light for providing a collimated beam of light, at least one selector mirror capable of being positioned in at least two positions to redirect the beam of light in two different beam paths, the first beam path being a direct exit beam path wherein the selector mirror redirects the beam of light along an exit beam path to provide a first illumination mode, the second beam path is a mirror loop path comprising two or more mirrors arranged to redirect the beam of light onto the selector mirror such that it is redirected by the selector mirror a second time along the exit beam path, and wherein mirror loop path comprises at least one optical element arranged to optically alter the beam of light to provide the second illumination mode. According to one embodiment, the first illumination mode is total internal reflection (tirf) and the second illumination mode is photokinetics (pk) illumination..


Popular terms: [SEARCH]

Kinetics topics: Medical Device, Polypeptide, Nucleic Acid, Nucleic Acids, Specificity, Surfactant, Enhancement, Scattering, Electrolyte, Conductive Elements, Amplification, Red Blood Cell, Red Blood Cells, Antibodies, Luciferase

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Kinetics for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kinetics with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         















1.0622

3200

459291 - 0 - 71